An immunoradiometric assay (IRMA) IGF-II was measured in formic acid/acetone extracts of plasma from 16 normal subjects (mean 685, range 516\p=n-\1008 \ g = m \ g / l ) , four acromegalic patients (mean 637, range 553\p=n-\700 \ g = m\ g / l ) , fourteen patients with type-1 diabetes (mean 635, range 247\p=n-\753 \g=m\g/l ), nine patients with uraemia (mean 423, range 78\p=n-\850 \g=m\g/l), and three patients with Laron-type GH insensitivity (75, 35 and 36 \g=m\g/l). No significant fluctuations were detected between samples obtained hourly from 08.00 to 19.00 h in normal subjects.
monoclonal antibodies (MAbs) to recombinant human IGF-II (rhIGF-II) were produced, all of which had low cross-reactivity with rhIGF-I (< 0\m=.\01%) and insulin (< 0\m=.\01%). Compatibility of pairs of MAbs was tested in two-site IRMAs using three radioiodinated MAbs and three MAbs linked to Sephacryl S-300 (with separation of bound and free radiolabelled MAb by sucrose layering). Seven pairs of MAbs bound rhIGF-II and the combination of 125I-labelled W3D9 and W2H1 linked to solid phase was selected. The optimized assay had a completion time of 4 h, a minimum detection limit of 30 ng/ml (2\m=.\5 standard deviations from the zero standard) and detected a single peak of endogenous IGF-II in normal plasma which co-eluted with rhIGF-II after acid gel chromatography.
IGF-II was measured in formic acid/acetone extracts of plasma from 16 normal subjects (mean 685, range 516\p=n-\1008 \ g = m \ g / l ) , four acromegalic patients (mean 637, range 553\p=n-\700 \ g = m\ g / l ) , fourteen patients with type-1 diabetes (mean 635, range 247\p=n-\753 \g=m\g/l ), nine patients with uraemia (mean 423, range 78\p=n-\850 \g=m\g/l), and three patients with Laron-type GH insensitivity (75, 35 and 36 \g=m\g/l). No significant fluctuations were detected between samples obtained hourly from 08.00 to 19.00 h in normal subjects.
Low levels of IGF-binding proteins (IGFBPs) remaining in plasma extracts may interfere with the measurement of IGF-II and give rise to falsely elevated IGF-II levels in radioimmunoassays or falsely suppressed levels in IRMAs. Such interference did not occur with the IRMA when used to measure IGF-II in extracts from normal subjects, acromegalic patients and patients with type-1 diabetes, and the addition of excess rhIGF-I in order to displace IGF-II from residual IGFBPs had no effect on IGF-II measurements in these samples. However, levels of IGF-II measured in extracts from patients with Laron-type GH insensitivity and patients with uraemia increased markedly after preincubation with excess rhIGF-I. The accurate measurement of IGF-II by IRMA in extracts from these subjects therefore requires the displacement of IGF-II from IGFBPs prior to assay. We conclude that, in contrast to radioimmunoassays, the two-site IRMA developed here provides a practical, rapid and specific method for the measurement of
INTRODUCTION
In the years since the identification of insulin-like growth factor I (IGF-I) and IGF-II as distinct com¬ ponents of non-suppressible insulin-like activity in human serum (Rinderknecht & Humbel, 1978a,6) there has been a marked divergence in our understanding of the relative roles of circulating IGFs in human physiology. While IGF-I is recognized to have a major role in growth regulation as the predominant mediator of growth hormone (GH) action, much less is known about IGF-II. A developmental role for IGF-II has been suggested (Romanus et al. 1988) and demonstrated by De Chiara et al. (1990) individually ( Fig. 2 and b respectively) and by IRMA (Fig. 3 ) Plasma levels of IGF-II Figure 4 shows the IGF-II levels measured in plasma taken at 09.00 h from 16 normal subjects, 14 patients with type-1 diabetes, four acromegalie patients, nine patients with uraemia in whom plasma creatinine levels were above 1000 pmol/1 and three patients with Laron-type GH insensitivity. IGF-II in normal sub¬ jects ranged between 516 and 1008 pg/1 (mean 685 pg/1), and similar levels were found in plasma from the four acromegalie patients under study (mean 685 pg/1, range 553-700 pg/1). IGF-II levels in (Cotterill et al. 1991) is not yet known.
At the present time the precise calibration of IGF-II immunoassays is insecure because there is no international reference preparation of IGF-II. According to our internal standardization, we found that plasma IGF-II levels in normal subjects were four-to fivefold higher than the corresponding IGF-I figure 6. Plasma IGF-II measured at hourly intervals in a normal subject between 08.00 and 19.00 h, together with the range of plasma IGF-II levels for eight normal subjects (shaded area 
